First Tracks Biotherapeutics, C3.ai, CCC Intelligent Solutions And Other Big Stocks Moving Higher On Monday

First Tracks Biotherapeutics (NASDAQ: TRAX) shares surged 18% to $37.36 following positive topline results from its Phase 1b clinical trial of ANB033 for celiac disease, which demonstrated protection against gluten-induced intestinal damage. Other notable gainers included C3.ai (NYSE: AI), which rose 10.7% to $12.75 after an upgrade by Northland, and CCC Intelligent Solutions (NASDAQ: CCC), which gained 7.6% to $7.55 amid acquisition talks involving GTCR and Elliott Investment Management.